Biological treatment for rheumatoid arthritis: a review of the main approved monoclonal antibodies

José Hidalgan Galdino Faustino1, Douglas Henrique de Oliveira1, Thais Cristina Casimiro Fernandes2, Patricia UcelliSimioni3
1Bachelor’s in biomedical science Faculdade de Americana, FAM.
2PhD in Cellular and Molecular Biology, Faculdade de Americana, FAM.
3PhD in Immunology, Faculdade de Americana, FAM.

Worldwide Medicine 2019; 1(6): 184-191 | DOI: 10.5455/ww.53482      PDF


Rheumatoid arthritis (RA) is a condition that affects mobility and the quality of life of the patient by affecting small and large joints and other organs. Its etiology is unknown, and its main characteristic is bone erosion and synovial inflammation. The conventional treatments involve the use of corticosteroids, immunosuppressants and antiinflammatory drugs. A very effective new therapeutic option is the biological therapy with monoclonal antibodies. The monoclonal antibody therapy is highly specific but also with side effects. The present work details the application of biological therapies based on monoclonal antibodies for the treatment of RA patients. In this sense, cytokine-drive monoclonal antibodies may control or inhibit the immune response in RA. This therapeutic possibility has as a response the reduction of structural and joint damage.

Keywords: Arthritis, therapy, antibody, monoclonal, biological, cytokine